News | February 23, 2024
Moderna posts Q4 2023 revenue at US$ 2.8 billion
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Beneficiaries can create Ayushman Card from their mobile phone using Ayushman App which has been downloaded 52 lakh times since its launch on 13th September, 2023
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
